What is it about?
Hepatoblastomas are primary liver tumors in children composed of primitive embryonic cells. In our practice, we routinely conduct a panel of immunostains to better characterize these tumors. Herein, we performed a retrospective review of 62 hepatoblastomas allowing for assessment of EpCAM expression using a commercially available antibody.
Photo by Yassine Khalfalli on Unsplash
Why is it important?
The histotype-based expression patterns of EpCAM correspond with previous molecular studies suggesting its role in the identification of aggressive forms of hepatoblastomas and as a possible therapeutic target. Our series offers validation of these observations from an immunohistochemical perspective and underscores the value of this marker as a part of a panel of immunostains.
Read the Original
This page is a summary of: Immunohistochemical Expression Analysis of EpCAM in Hepatoblastomas, Applied Immunohistochemistry & Molecular Morphology, December 2019, Wolters Kluwer Health, DOI: 10.1097/pai.0000000000000826.
You can read the full text:
Hepatic Stem-like Phenotype and Interplay of Wnt/β-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer
Abstract: Hepatoblastoma, the most common pediatric liver cancer, is tightly linked to excessive Wnt/beta-catenin signaling. Here, we used microarray analysis to identify two tumor subclasses resembling distinct phases of liver development and a discriminating 16-gene signature.
The diagnostic and prognostic value of SALL4 in hepatoblastoma.
AIMS: To investigate the expression of spalt-like transcription factor 4 (SALL4), a regulator of embryonal development, in three epithelial components of hepatoblastoma (HB) and the relationship between SALL4 expression levels and patients' clinicopathological features.
The following have contributed to this page